Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Celgene May Bid for Human Genome, Reuters Says

(Corrects to say second bidder will propose merger of equals in second paragraph)

July 8 (Bloomberg) -- Celgene Corp. is one of two companies other than GlaxoSmithKline Plc weighing a bid for Human Genome Sciences Inc., Reuters says, citing a source familiar with the situation that it didn’t identify.

A second unidentified bidder would propose a merger of equals, Reuters said yesterday. Glaxo has offered to buy Human Genome for $13 a share, and the U.S. biotechnology company has set a July 16 deadline for competing bids.

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editor responsible for this story: Dick Schumacher at dschumacher@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.